secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001070081-23-000048
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q2 revenue $214M (+29% YoY); raises full-year guidance to $940M-$1.0B
--------------------------------------------------------------------------------

- Total revenue $213.8M vs $165.5M Q2 2022; DMD franchise $162M (+21%).
- Translarna net revenue $96.5M; Emflaza $65.7M; Evrysdi royalties $36.9M.
- Sepiapterin APHENITY trial met primary endpoint; NDA filing planned Q4 2023.
- GAAP net loss $198.9M; cash $337.9M; gene therapy discontinues caused $88M non-cash charge.
- Full-year 2023 total revenue guidance raised to $940M-$1.0B; DMD product revenue guidance $545-$575M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000048/0001070081-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000048/tmb-20230803x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer